Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin Lymphoma (HL): data from UKLG LY09 (ISRCTN97144519)

Owadally, Waheeda, Sydes, Matthew, Radford, John, Hancock, Barry, Cullen, Michael, Stenning, Sally and Johnson, Peter (2009) Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin Lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Annals of Oncology. (In Press)

Abstract

Background: This analysis was undertaken to assess the relationship between the dose intensity of initial chemotherapy and outcome in a large cohort of patients with advanced Hodgkin lymphoma (HL) treated in a randomised controlled trial, in which detailed dose data were collected prospectively.
Patients and methods: Three hundred eighty patients randomised to receive standard ABVD who underwent at least 2 cycles of treatment were studied. With a median follow up of 6.9 years, progression-free survival (PFS) from the end of cycle 2 was analysed according to dose intensity (DI) during those cycles.
Results: During the first 2 cycles, 25% of patients received more than 97% of planned DI, 37% received between 86% and 97% and 38% received less than 86%. DI during the first 2 cycles was correlated with DI during the remainder of the course, but there was no evidence that early DI influenced PFS (hazard ratio 0.87, 95% CI 0.67-1.11; p=0.265). Multivariate analysis also failed to confirm the influence of early DI on PFS or overall survival (OS).
Conclusion: At the range of DI delivered in a multicentre trial using conventional therapy, there is no clear evidence that early DI influences outcome. This should be tested in a prospective study.

This record has no associated files available for download.

Contributors

Author: Peter Johnson

Download statistics